E
Enveda Biosciences
Engineering new drugs from nature with knowledge graphs, metabolomics, and ML
Open roles
Enveda Biosciences in the Boulder ecosystem
The Enveda Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Village Global
True Ventures- CGChris Gibson
- WVWireframe Ventures
Series A6 investors entered at this stage
- LCLifeforce Capital
- CMCatalio Capital Management
Two Sigma Ventures
Hummingbird Ventures
Lux Capital- MSMatthew De Silva
Series B and later18 investors entered at this stage
- LMLingotto Investment Management
- HKHenry Kravis
Premji Invest
Microsoft- DIDimension
- ACAmino Collective
- LVLevel Ventures
- FVFPV Ventures
- JPJAZZ Venture Partners
Baillie Gifford- PPPeakline Partners
- SASanofi
Kinnevik- SVSocium Ventures
IA Ventures- TCThe Nature Conservancy
- UCUniversity of California
- SDSan Diego
Ownership
Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.
Some investors are hidden on this public profile. See the full cap table on Dealroom →
Source: Dealroom Talent Intelligence.
Patents
6 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Enveda Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Anthropic buys Mithril Medicine, a one-person biotech that ran a muscular dystrophy drug programme with Claude
Enveda's $311M bet: sequencing life's chemical code
Enveda raises $311M Series E to scale AI drug discovery